πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 77 of 151

  1. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1

    phase 2 small molecule terminated

    1 trial

  2. Losmapimod

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  3. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial

  4. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial

  5. Losmapimod oral tablet

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 2 small molecule completed

    1 trial

  6. Lotilaner Gel, 2.0%

    Tarsus Pharmaceuticals

    Papulopustular Rosacea

    phase 2 small molecule completed

    1 trial

  7. Lovaza, omega-3 fatty acid ethyl ester

    United Therapeutics Europe Ltd

    Mood Disorders

    phase 2 small molecule active

    1 trial

  8. Low Dose ARD-501

    Ark Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule completed

    1 trial

  9. Low Dose GC4419: 30mg/day

    Galera Therapeutics

    Radiation Induced Oral Mucositis

    phase 2 small molecule completed

    1 trial

  10. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  11. Low Dose Modafinil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  12. Low Dose SKY0402

    Pacira Ireland Limited

    Postoperative Pain

    phase 2 small molecule terminated

    1 trial

  13. Low Dose TP-05

    Tarsus Pharmaceuticals

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  14. Low Molecular Weight Heparin (LMWH)

    Cardiff Oncology

    Cancer

    phase 2 small molecule terminated

    1 trial

  15. Low dose FRΞ± vaccine

    Marker Therapeutics

    Breast Cancer

    phase 2 mab completed

    1 trial

  16. Low dose LX2006

    Lexeo Therapeutics

    Friedreich Ataxia

    phase 2 gene therapy active

    1 trial

  17. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  18. Low-dose ASA

    Atrium Therapeutics

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  19. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  20. Low-dose experimental vaccine

    Sinovac Research and Development Co.,

    Herpes Zoster

    phase 2 mab active

    1 trial

  21. Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease (HFMD)

    phase 2 mab completed

    1 trial

  22. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 small molecule terminated

    1 trial

  23. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  24. Lubiprostone

    Takeda

    Irritable Bowel Syndrome

    phase 2 small molecule terminated

    3 trials

  25. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    COVID-19

    phase 2 small molecule completed

    1 trial

  26. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Acute Hypoxemic Respiratory Failure

    phase 2 small molecule completed

    1 trial

  27. Lucinactant 175 mg/kg

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 small molecule terminated

    1 trial

  28. Lucinactant delivered via investigational delivery device

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 small molecule completed

    1 trial

  29. Lucinactant first

    WINDTREE THERAPEUTICS INC /DE/

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  30. Lucinactant for Inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 other terminated

    1 trial

  31. Lucinactant for inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 other terminated

    2 trials

  32. Lumasiran

    Alnylam Netherlands B.V.

    Haemodialysis

    phase 2 small molecule active

    1 trial

  33. Lumasiran

    Alnylam Netherlands B.V.

    Recurrent Calcium Oxalate Kidney Stone Disease

    phase 2 small molecule terminated

    1 trial

  34. Lumasiran

    Alnylam Netherlands B.V.

    PH1

    phase 2 small molecule completed

    1 trial

  35. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 2 small molecule completed

    1 trial

  36. Lumevoq

    GenSight Biologics S.A.

    Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene

    phase 2 small molecule active

    1 trial

  37. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  38. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Viruses

    phase 2 small molecule terminated

    1 trial

  39. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  40. Lunsekimig

    Sanofi Pasteur

    Asthma

    phase 2 small molecule active

    1 trial

  41. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Soft-tissue Sarcoma

    phase 2 small molecule active

    1 trial

  42. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  43. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Refractory Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  44. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Locally Advanced Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  45. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive-stage Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  47. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  48. Lurbinectedin 4 MG Injection [Zepzelca]

    Jazz Pharmaceuticals Ireland Limited

    Gastrointestinal Malignancies

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.